NeuroSense Therapeutics – Study of New Drug to Treat ALS

Alon Ben-Noon, CEO and co-founder of NeuroSense Therapeutics, a clinical-stage biotechnology company focused on treatments for neurodegenerative diseases discusses the recent FDA clearance to initiate a pharmacokinetic study of PrimeC.

Click below to listen to the full interview.


Join Our Newsletter

Skip to content